AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32979577
Drug: Development of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Development of IgG anti-N-methyl-D-aspartate receptor (NMDAR) antibodies
Trial: 32652616
Drug: Cannabidiol (CBD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol (CBD; 20 mg/kg/day)
Trial: 32652616
Drug: Cannabidiol (CBD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol (CBD; 20 mg/kg/day) with clobazam (CLB)
Trial: 36083324
Drug: High-volume injection
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume injection (HVI) - 50 mL
Trial: 36083324
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection - 2 mL (saline and lidocaine)
Trial: 36083324
Drug: High-volume injection
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume injection (HVI)
Trial: 37638083
Drug: Methadone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (0.2 mg/kg)
Trial: 33487095
Drug: Electronic stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic stimulation (ES) administered to bilateral lower legs using tapping mode (3 Hz)
Trial: 34051006
Drug: 50 µl
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µl Receptal solution
Trial: 34051006
Drug: 100 µl
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µl Receptal solution
Trial: 34051006
Drug: 150 µl
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 µl Receptal solution
Trial: 32601101
Drug: Colon capsule
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon capsule endoscopy (CCE) as a filter test prior to faecal immunochemical test (FIT)
Trial: 33895547
Drug: internet‐delivered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet‐delivered cognitive behavioral treatment that included exposure (ICBT)
Trial: 33895547
Drug: internet‐delivered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet‐delivered cognitive behavioral treatment without exposure (ICBT‐WE)
Trial: 35696698
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg capsules
Trial: 35696698
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (Becosules)
Trial: 32248747
Drug: JNJ-54175446 (50-450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54175446 (50-450 mg)
Trial: 32248747
Drug: JNJ-54175446 (≥100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54175446 (≥100 mg)
Trial: 34627490
Drug: De-escalation (clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalation (clopidogrel plus aspirin)
Trial: 34627490
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control (ticagrelor plus aspirin)
Trial: 35296491
Drug: Multinutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multinutrient supplement including vitamin D, tryptophan, long‐chain polyunsaturated fatty acids, and prebiotic dietary fibres (94 kCal per daily dose)
Trial: 35296491
Drug: Multinutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multinutrient supplement
Trial: 32417629
Drug: Melatonin 10
RxNorm normalized name: melatonin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 10 mg (two capsules of 5 mg each) once a day, 1 hour before bedtime for 12 weeks
Trial: 35668528
Drug: Ruxolitinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib combined with 1 mg/kg methylprednisolone
Trial: 35668528
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg methylprednisolone alone
Trial: 32543247
Drug: Enoxaparin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.75 mg/kg intra-arterial bolus followed by 0.75 mg/kg/6 hours intravenous infusion)
Trial: 32543247
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) with unfractionated heparin ± glycoprotein IIb/IIIa antagonist (GPI)
Trial: 33258423
Drug: 1×10^5/ml spore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1×10^5/ml spore suspension
Trial: 35873761
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no acupuncture treatment and ASD)
Trial: 33827963
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of human adrenomedullin (19.9 pmol/kg/min)
Trial: 35493500
Drug: Rituximab (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (maintenance therapy)
Trial: 33568796
Drug: Topiramate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (200 mg daily for 12 weeks)
Trial: 36401384
Drug: Endoscopic variceal
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic variceal obturation (EVO) with tissue glue injection
Trial: 35857179
Drug: Tralokinumab 300
RxNorm normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab 300 mg subcutaneous every 2 weeks (q2w) plus topical corticosteroids (TCS) as needed
Trial: 33000503
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus topical corticosteroids (TCS) as needed
Trial: 34371870
Drug: 2.6 g
RxNorm normalized name: SODIUM BICARBONATE 2.6 g in 2.6 g ORAL POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.6 g marine n‐3 PUFA supplement
Trial: 35012809
Drug: Colloid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid group (6% hydroxyethyl starch 130/0.4 10 mL/kg)
Trial: 35012809
Drug: Crystalloid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid group (balanced crystalloid solution, Plasma Solution A 10 mL/kg)
Trial: 33571166
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment mentioned)
Trial: 36387986
Drug: (poly)phenol-rich supplement
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (poly)phenol-rich supplement 1,200 mg/day + hypocaloric diet
Trial: 35576997
Drug: Creative Arts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creative Arts Therapy (CAT) program
Trial: 33105308
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of TXA bolus/1 g of TXA infusion (bolus maintenance)
Trial: 33105308
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of TXA bolus/placebo infusion (bolus only)
Trial: 33105308
Drug: Placebo bolus/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bolus/placebo infusion (placebo)
Trial: 34619312
Drug: Allele 'G'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allele 'G' of rs58379944 and rs11574012; Allele 'A' of rs12581281
Trial: 35485346
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of JNJ-64530440 (up to 4000 mg)
Trial: 35485346
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of JNJ-64530440 (750 mg once daily and 2000 mg for 7 days)
Trial: 35485346
Drug: Single and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple doses of JNJ-64530440
Trial: 34840276
Drug: Solid Ankle
RxNorm normalized name: Bos taurus ankle joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid Ankle Foot Orthosis (AFO) with regular physical therapy for 3 months
Trial: 34840276
Drug: Ground Reaction
RxNorm normalized name: Turmeric,ground
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground Reaction Ankle Foot Orthosis (GRAFO) with regular physical therapy for 3 months
Trial: 32043473
Drug: Prehospital intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital intravenous antibiotics
Trial: 33220122
Drug: CM for
RxNorm normalized name: Chondroitin/Dimethyl Sulfone/Glucosamine Sulfate/Inflexil 250 MG-250 MG-500 MG-7.5 MG Oral Tablet [LEGATRIN GCM FORMULA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM for drugs (n = 27)
Trial: 33220122
Drug: CM for
RxNorm normalized name: Chondroitin/Dimethyl Sulfone/Glucosamine Sulfate/Inflexil 250 MG-250 MG-500 MG-7.5 MG Oral Tablet [LEGATRIN GCM FORMULA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM for alcohol and drugs (n = 32)
Trial: 36339874
Drug: Humanoid robot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanoid robot intervention (Grace humanoid robot, 8-week, twice a week)
Trial: 36339874
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (active control)
Trial: 33512755
Drug: Omarigliptin 25
RxNorm normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omarigliptin 25 mg
Trial: 33202093
Drug: YH12852 0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH12852 0.3, 0.5, 1, 2, or 3 mg
Trial: 33202093
Drug: YH12852 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH12852 0.05 or 0.1 mg
Trial: 33202093
Drug: YH12852 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH12852 (all doses)
Trial: 32359393
Drug: Qing Qiao
RxNorm normalized name: qing feng teng stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qing Qiao Capsule
Trial: 32359393
Drug: Caefaclor capsule
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caefaclor capsule (Control)
Trial: 35661157
Drug: Neoadjuvant ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant ipilimumab 1 mg kg−1 and nivolumab 3 mg kg−1 for 6 weeks
Trial: 35661157
Drug: TLND and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLND and adjuvant systemic therapy ± synchronous radiotherapy for patients with pathologic non-response (pNR)
Trial: 33957336
Drug: Tiagabine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (15 mg)
Trial: 35001439
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (CP) administration as a complement to standard treatment
Trial: 35001439
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus non-convalescent plasma (control)
Trial: 35904750
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (acetyl-salicylic acid plus a P2Y12 inhibitor)
Trial: 35904750
Drug: Antiplatelet monotherapy
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet monotherapy (a P2Y12 inhibitor) plus low dose anticoagulant (rivaroxaban, 15mg oral dose)
Trial: 32927668
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g per day of cocoa-rich chocolate (99%) for 6 months
Trial: 36217289
Drug: Rabbit Anti-Thymocyte
RxNorm normalized name: Rabbit anti-thymocyte immunoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit Anti-Thymocyte Globulin (rATG) 5 mg/kg from days -5 to -2
Trial: 33333285
Drug: Prednisone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (10 mg, qd, from the first day postoperatively, for 2 weeks)
Trial: 33333285
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine analgesic regimens including injection of cocktail mixture intraoperatively, oral celecoxib and tramadol postoperatively)
Trial: 33977506
Drug: Losartan 12.5
RxNorm normalized name: losartan 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 12.5 mg orally every 12 h for 10 days plus standard of care (SOC)
Trial: 32114516
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) and optimal medical therapy (OMT)
Trial: 35312632
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg)
Trial: 34283529
Drug: Neurouridin dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neurouridin dietary supplement
Trial: 32105112
Drug: Concurrent Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Treatment of PTSD and Substance Use Disorder Using Prolonged Exposure (COPE)
Trial: 34981420
Drug: IV norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV norepinephrine + oral midodrine 10 mg thrice a day
Trial: 35316858
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy along with conscious sedation (Group A)
Trial: 32098012
Drug: Propofol-based anesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-based anesthesia (intravenous anesthetic)
Trial: 32512710
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of porcine placenta extract once daily for 4 weeks
Trial: 616172503
Drug: NT-proBNP guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP guided therapy (group 1)
Trial: 616172503
Drug: Standard heart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heart failure therapy (group 2)
Trial: 35861908
Drug: Class IIa
RxNorm normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class IIa medical device containing lactic acid, azelaic acid/polyglyceryl‐3 copolymer, azelamidopropyl dimethyl amine, and bifida ferment lysate, used twice daily for 2 months
Trial: 34265576
Drug: Plantago major
RxNorm normalized name: Plantago major
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plantago major seed (3600 mg/day)
Trial: 33334195
Drug: Xylitol tablets
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol tablets with red propolis (XPT)
Trial: 33334195
Drug: Xylitol tablets
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol tablets without red propolis (XT)
Trial: 32546239
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment for 6 months
Trial: 33772845
Drug: Pramlintide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide infusion
Trial: 36479786
Drug: Early glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early glargine group (subcutaneous insulin glargine 0.3 units/kg within the first 3 hours of DKA diagnosis, in addition to standard IV insulin infusion)
Trial: 36479786
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard IV insulin treatment only)
Trial: 32930090
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to an equivalent dose of quetiapine, aripiprazole, or olanzapine with brief psychoeducation and support.
Trial: 33533074
Drug: Melasolv™ applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melasolv™ applied twice a day for 12 weeks
Trial: 33533074
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied twice a day for 12 weeks
Trial: 34477291
Drug: Home Treatment
RxNorm normalized name: Home-brew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home Treatment (HT)
Trial: 34699618
Drug: Nitazoxanide 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 1,500 mg orally twice-daily with food for 7 days
Trial: 33771722
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 80 μg via Breezhaler® (low-dose ICS)
Trial: 33771722
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 320 μg via Breezhaler® (high-dose ICS)
Trial: 33771722
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate via Breezhaler® (50-400 μg)
Trial: 33771722
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate via Twisthaler® (200 μg and 800 μg)
Trial: 32429874
Drug: Less invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less invasive surfactant administration via nasal route (LISA-n)
Trial: 36253574
Drug: Adjunctive virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive virtual classroom training (VCT) with the FRS curriculum
Trial: 36253574
Drug: Adjunctive virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive virtual classroom training (VCT) after initial training with FRS curriculum
Trial: 34587568
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) intervention
Trial: 36235546
Drug: Enhanced parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced parenteral nutrition (higher glucose infusion rate and intralipids)
Trial: 36235546
Drug: Enhanced parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced parenteral nutrition
Trial: 32801649
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of amitriptyline hydrochloride (25 mg)
Trial: 32801649
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of amitriptyline hydrochloride (25 mg)
Trial: 34887325
Drug: High-dose prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisolone
Trial: 36053364
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g kg-1 body mass NaHCO3 in chilled orange squash
Trial: 36053364
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g kg-1 body mass NaHCO3 in capsules
Trial: 36053364
Drug: Placebo (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.03 g kg-1 body mass sodium chloride)
Trial: 33830626
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec 100 units/mL (degludec)
Trial: 33280425
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 units/mL (glargine U100)
Trial: 33825140
Drug: Vitamin-K1 [10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-K1 [10 mg/day]
Trial: 33825140
Drug: Colchicine [0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine [0.5 mg/day]
Trial: 34916643
Drug: Four-implant overdentures
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-implant overdentures in the maxilla
Trial: 33202169
Drug: Domperidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (10 mg, 2 tablets three times a day for 14 days)
Trial: 32200486
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus metformin
Trial: 38838170
Drug: Adjuvanted recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted recombinant zoster vaccine (RZV)
Trial: 34315695
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (2 g sachet daily)
Trial: 34315695
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no probiotic supplements)
Trial: 37700375
Drug: Metformin intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin intervention
Trial: 36004716
Drug: Placebo suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension
Trial: 36402160
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo capsules
Trial: 35560315
Drug: Fortified BEP
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fortified BEP supplements and IFA
Trial: 37126332
Drug: Xuebijing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing injection
Trial: 34938352
Drug: Sulfadiazine Silver
RxNorm normalized name: Sulfadiazine silver
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfadiazine Silver Cream (SSC)
Trial: 32869324
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from warfarin to a direct oral anticoagulant after hospitalization